These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 30910327)

  • 1. Prevention of decompensation in cirrhosis: a new youth for β blockers.
    Levy S; Samuel D
    Lancet; 2019 Apr; 393(10181):1571-1572. PubMed ID: 30910327
    [No Abstract]   [Full Text] [Related]  

  • 2. In compensated cirrhosis with portal hypertension, β-blockers reduced a composite of decompensation or death.
    Korula J
    Ann Intern Med; 2019 Aug; 171(4):JC21. PubMed ID: 31426064
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
    Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
    Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Beta-blockers and the prevention of decompensation in cirrhosis: worth the trouble.
    Northup PG; Henry ZH
    Am J Gastroenterol; 2012 Mar; 107(3):428-30. PubMed ID: 22388023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.
    Reverter E; Mesonero F; Seijo S; Martínez J; Abraldes JG; Peñas B; Berzigotti A; Deulofeu R; Bosch J; Albillos A; García-Pagán JC
    Am J Gastroenterol; 2015 Jul; 110(7):985-92. PubMed ID: 26077176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Kleefisch M; Lange C; Wedemeyer H
    MMW Fortschr Med; 2019 Nov; 161(20):39. PubMed ID: 31773605
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers.
    Hernández-Gea V; Aracil C; Colomo A; Garupera I; Poca M; Torras X; Miñana J; Guarner C; Villanueva C
    Am J Gastroenterol; 2012 Mar; 107(3):418-27. PubMed ID: 22334252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term drug treatments to improve prognosis of patients with liver cirrhosis and to prevent complications due to portal hypertension].
    Holstege A
    Z Gastroenterol; 2019 Aug; 57(8):983-996. PubMed ID: 31398770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Beta blockers and cirrhosis-more than just portal hypertension?
    Ttl Tjwa E
    Aliment Pharmacol Ther; 2021 Mar; 53(5):644-645. PubMed ID: 33566416
    [No Abstract]   [Full Text] [Related]  

  • 11. β blockers in liver cirrhosis.
    Triantos C; Thomopoulos K; Lampropoulou-Karatza C
    Gastroenterology; 2014 Oct; 147(4):941. PubMed ID: 25171876
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuation of nonselective beta-blockers for patients with liver cirrhosis and hemodynamic nonresponse?
    Sauerbruch T
    Hepatology; 2017 Oct; 66(4):1362-1363. PubMed ID: 28734120
    [No Abstract]   [Full Text] [Related]  

  • 13. [Advanced liver cirrhosis: beta blockers seem harmful].
    Lutz HH; Tischendorf JJ
    MMW Fortschr Med; 2014 Nov; 156 Spec no 2():35. PubMed ID: 25552015
    [No Abstract]   [Full Text] [Related]  

  • 14. Beta adrenergic blockade and decompensated cirrhosis.
    Reiberger T; Mandorfer M
    J Hepatol; 2017 Apr; 66(4):849-859. PubMed ID: 27864004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Beta-blockers and portal hypertension].
    Rueff B
    Rev Prat; 1984 Apr; 34(19):979-80. PubMed ID: 6144165
    [No Abstract]   [Full Text] [Related]  

  • 16. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.
    Groszmann RJ; Garcia-Tsao G; Bosch J; Grace ND; Burroughs AK; Planas R; Escorsell A; Garcia-Pagan JC; Patch D; Matloff DS; Gao H; Makuch R;
    N Engl J Med; 2005 Nov; 353(21):2254-61. PubMed ID: 16306522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: "THE THERAPEUTIC WINDOW".
    Dimache M; Gîrleanu I; Carpov E; Trifan A; Stanciu C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):23-8. PubMed ID: 27125068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
    Schepke M; Wiest R; Flacke S; Heller J; Stoffel-Wagner B; Herold T; Ghauri M; Sauerbruch T
    Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers to prevent gastroesophageal varices in cirrhosis.
    Post AB
    N Engl J Med; 2006 Mar; 354(12):1318-20; author reply 1318-20. PubMed ID: 16554538
    [No Abstract]   [Full Text] [Related]  

  • 20. Nadolol reduces insulin sensitivity in liver cirrhosis: a randomized double-blind crossover trial.
    Lee WG; Murphy R; McCall JL; Gane EJ; Soop M; Tura A; Plank LD
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.